Previous 10 | Next 10 |
home / stock / rhhvf / rhhvf news
2024-02-11 07:04:47 ET Summary Roche is a well-recognized pharmaceutical company with a strong international presence and a market capitalization of CHF 187 billion. Despite recent challenges, Roche's 2024 guidance shows potential for mid-single-digit growth in revenues and EPS, m...
2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...
2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-02-01 22:52:09 ET Start Time: 09:30 End Time: 11:31 Roche Holding AG (RHHBY) Q4 2023 Earnings Conference Call February 01, 2024, 09:30 AM ET Company Participants Thomas Schinecker - CEO Roche Group Teresa Graham - CEO Roche Pharmaceuticals Matt Sause...
2024-02-01 03:48:34 ET More on Roche Holding: Roche: Leveraging Nvidia's AI For Genentech's Innovation Roche ends AC Immune partnership for Alzheimer’s drugs Roche, Remix Therapeutics sign license deal Historical earnings data for Roche Holding AG ...
2024-01-12 13:46:01 ET Summary Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID product revenues sufficiently de-risks for related h...
2024-01-09 18:04:24 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...
2024-01-04 16:28:54 ET Summary Today, we take a look at Blueprint Medicines Corporation, whose shares have nearly doubled in the past two months due to strong sales of its precision medicine Ayvakit. Ayvakit's label expansion into indolent systemic mastocytosis suggests blockbuste...
2023-12-29 16:11:47 ET Summary Positive results achieved from phase 1 dose expansion study using luveltamab tazevibulin for the treatment of patients with FRa-positive endometrial cancer. Phase 1 dose expansion study, using luveltamab tazevibulin in FRa-positive endometrial cancer...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Div Rts Company Name:
RHHVF Stock Symbol:
OTCMKTS Market:
Roche Holding Div Rts Website:
Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care Canada NewsWire At the global HIMSS 1 Conference, Roche showcases navify Algorithm Suite, a single platform offering cli...
Roche Announces Brad Moore as President and CEO of Roche Diagnostics North America PR Newswire INDIANAPOLIS , Dec. 5, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Brad Moore as president and CEO of Roche Diagnost...